Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (INSIGHTS-IPF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01695408
Recruitment Status : Recruiting
First Posted : September 28, 2012
Last Update Posted : February 4, 2021
Boehringer Ingelheim
Information provided by (Responsible Party):
Technische Universität Dresden

Brief Summary:
Idiopathic pulmonary fibrosis (IPF), a manifestation of chronic progressive fibrosing interstitial pneumonia,ia a rare disease. Current treatment options are limited, and the mean survival time of the newly diagnosed (mostly elderly) patients is only about 2-3 years. As in Europe data are limited on the characteristics and management of such patients, INSIGHTS-IPF was initiated as a new registry that documents newly diagnosed (incident) and prevalent patients with confirmed IPF diagnosis prospectively.The registry will contribute to the optimization of the management of IPF patients in the long term.

Condition or disease
Idiopathic Pulmonary Fibrosis

Detailed Description:

INSIGHTS-IPF will report current and comprehensive data on Idiopathic Pulmonary Fibrosis (IPF) in the long-term.

Baseline (cross-sectional part): Description of characteristics of IPF patients in terms of

  • key (socio-) demographic data
  • IPF risk factors, comorbidities
  • methods used for IPF diagnosis
  • IPF disease severity and manifestation (including lung function, cardiopulmonary exercise testing and/or exercise capacity if available, laboratory values, biomarkers)
  • IPF treatment (detailed information on prescribed drugs and doses; non-pharmacological treatment; listing and score for lung transplantation)
  • assessment of patient-related outcomes (PRO) such as quality of life

Follow-up (prospectively up to at least 2 years after inclusion):

  • Clinical course of IPF (e.g. in terms of symptoms, lung function, exercise capacity if available)
  • Documentation of treatment pathways (switch/add-on/discontinuation of medication), and of non-pharmacological treatment (e.g. start of long term oxygen therapy; new listing for lung transplantation)Outcomes/events (such as acute respiratory worsening, exacerbations, hospitalisation due to any cause and due to IPF, other complications, survival)
  • Patient-related outcomes such as quality of life, assessed once a year(for comparison with baseline)
  • Resource use for pharmacoeconomic analyses.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Investigating Significant Health Trends in IPF (INSIGHTS-IPF). Nationwide Prospective Registry.
Actual Study Start Date : October 2012
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : December 31, 2021

Primary Outcome Measures :
  1. Clinical course of IPF (in terms of symptoms, lung function, survival) [ Time Frame: up to 5 years after inclusion ]

Secondary Outcome Measures :
  1. Characteristics of patients with IPF [ Time Frame: up to 5 years after inclusion ]
  2. Treatment pathways [ Time Frame: up to 5 years after inclusion ]
  3. Functionality and quality of life [ Time Frame: up to 5 years after inclusion ]
    St. Georges Respiratory Questionnaire; University of California Shortness of Breath Questionnaire; EuroQuol 5 dimensions

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients with Idiopathic Pulmonary Fibrosis (confirmed diagnosis according to current ATS/ERS guidelines)

Inclusion Criteria:

  • At least 18 years of age
  • Written informed consent for participation in the registry
  • Newly diagnosed (incident) or known (prevalent) IPF (based on diagnosis of treating physician)

Exclusion Criteria:

  • None

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01695408

Layout table for location contacts
Contact: Juergen Behr, MD 089 85791 ext 4101
Contact: David Pittrow, MD, PhD +49 351 25933 ext 182

Layout table for location information
Institute for Clinical Pharmacology, Medical Faculty, Technical University Active, not recruiting
Dresden, Germany, 01307
Klinik für Pneumologie, Medizinische Hochschule Hannover Recruiting
Hannover, Germany
Contact: Antje Prasse, MD    +49511 532 ext 3934   
Principal Investigator: Antje Prasse, MD         
Pneumologie und Beatmungsmedizin, Thoraxklinik,Universitätsklinikum Recruiting
Heidelberg, Germany, 69126
Contact: Michael Kreuter, MD    +496221396 ext 1214   
Principal Investigator: Michael Kreuter, MD         
Abteilung für Pneumologie Department Innere Medizin, Neurologie und Dermatologie Universitätsklinikum Leipzig AöR Recruiting
Leipzig, Germany
Contact: Hubert Wirtz, MD   
Principal Investigator: Hubert Wirtz, MD         
V. Med. Clinic, Ludwig-Maximilians-Unviversity Recruiting
München, Germany
Contact: Jürgen Behr, MD         
Sponsors and Collaborators
Technische Universität Dresden
Boehringer Ingelheim
Layout table for investigator information
Principal Investigator: Juergen Behr, MD Asklepios Fachkliniken München Gauting Medizinischen Klinik und Poliklinik V Klinikum der Ludwig-Maximilians-Universität München Comprehensive Pneumology Center Munich (CPC-M) Mitglied des Deutschen Zentrums für Lungenforschung (DZL)
Study Chair: David Pittrow, MD Institute for Clinical Pharmacology, Medical Faculty, Technical University Dresden
Additional Information:
Publications of Results:

Other Publications:
Layout table for additonal information
Responsible Party: Technische Universität Dresden Identifier: NCT01695408    
Other Study ID Numbers: INSIGHTS-IPF
First Posted: September 28, 2012    Key Record Dates
Last Update Posted: February 4, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Technische Universität Dresden:
Drug Treatment
Treatment pathways
Clinical routine
Patient-related outcomes
Quality of life
Tyrosine kinase inhibitors
Adverse event
Additional relevant MeSH terms:
Layout table for MeSH terms
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Pathologic Processes
Lung Diseases
Respiratory Tract Diseases